Cargando…

BRCA1 c.4987-3C>G is a pathogenic mutation

Detalles Bibliográficos
Autores principales:	Brandão, Rita D., van Roozendaal, Kees E. P., Tserpelis, Demis, Caanen, Beppy, García, Encarna Gómez, Blok, Marinus J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2011
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249558/ https://www.ncbi.nlm.nih.gov/pubmed/22113256 http://dx.doi.org/10.1007/s10549-011-1878-3

Ejemplares similares

Detection of exon skipping events in BRCA1 RNA using MLPA kit P002
por: Brandão, Rita D., et al.
Publicado: (2012)

Targeted RNA‐seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes
por: Brandão, Rita D., et al.
Publicado: (2019)

Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers
por: Derks-Smeets, Inge A. P., et al.
Publicado: (2018)

Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection
por: van Harssel, J. J. T., et al.
Publicado: (2009)

The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine
por: Gorodetska, Ielizaveta, et al.
Publicado: (2015)

Multifactorial Likelihood Assessment of BRCA1 and BRCA2 Missense Variants Confirms That BRCA1:c.122A>G(p.His41Arg) Is a Pathogenic Mutation
por: Whiley, Phillip J., et al.
Publicado: (2014)

A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example
por: Mohammadi, Leila, et al.
Publicado: (2009)

Germline mutations in 5’ to c.7914 of BRCA2 significantly increase risk of prostate cancer
por: Ruan, Xiao-Hao, et al.
Publicado: (2022)

A Compound Mutation (c.953C<G and c.49G<A) Aggravates Functional Impairments of C1-INH in Hep G2 Cells
por: Xu, Ying-Yang, et al.
Publicado: (2018)

BRCA2 c.8827C>T pathogenic mutation in a consanguineous Chinese family with hereditary breast cancer
por: Wang, Jiangfen, et al.
Publicado: (2020)

Effect of the novel Moroccan BRCA1 and BRCA2 frameshift mutations
por: Tazzite, Amal, et al.
Publicado: (2013)

The BRCA1 c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic BRCA1 Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability
por: Arason, Adalgeir, et al.
Publicado: (2019)

Characterization of Synonymous BRCA1:c.132C>T as a Pathogenic Variant
por: Li, Jun, et al.
Publicado: (2022)

Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas
por: Weren, Robbert D.A., et al.
Publicado: (2016)

Novel heterozygous c.798C>G and c.1040T>G mutations in the GBA1 gene are associated with a severe phenotype of Gaucher disease type 1
por: Machaczka, Maciej, et al.
Publicado: (2014)

Comparison of Targeted Next-Generation and Sanger Sequencing for the BRCA1 and BRCA2 Mutation Screening
por: Park, Joonhong, et al.
Publicado: (2016)

The Novel Pathogenic Mutation c.849dupT in BRCA2 Contributes to the Nonsense-Mediated mRNA Decay of BRCA2 in Familial Breast Cancer
por: Li, Sanrong, et al.
Publicado: (2018)

Comment on ‘The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study'
por: Friedenson, Bernard
Publicado: (2016)

Comment on ‘The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study'
por: Paradiso, A V, et al.
Publicado: (2016)

Sanger Sequencing for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del Mutation Screen on Pap Smear Cytology Samples
por: Lee, Sin Hang, et al.
Publicado: (2016)

A Case of Antley-Bixler Syndrome With a Novel Likely Pathogenic Variant (c.529G>C) in the POR Gene
por: Oh, Jongwon, et al.
Publicado: (2017)

Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2019)

Response to ‘Comments on 'The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study''
por: Narod, Steven A
Publicado: (2016)

Integrative identification of the pathogenic role of a novel G6PD missense mutation c.697G>C
por: Zhang, Hongyang, et al.
Publicado: (2021)

Understanding Mental Distress: Knowledge, Practice and Neoliberal Reform in Community Mental Health Services. Rich Moth. Bristol: Policy Press; 2022. pp. 263 ISBN 978‐1‐4473‐4987‐7
por: McKeown, Mick
Publicado: (2022)

The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
por: C.E, Drechsel Katja, et al.
Publicado: (2022)

The Features of BRCA1 and BRCA2 Germline Mutations in Hakka Ovarian Cancer Patients: BRCA1 C.536 A>T Maybe a Founder Mutation in This Population
por: Luo, Yu, et al.
Publicado: (2022)

The First Case of Congenital Prekallikrein Deficiency in Korea With a Novel Pathogenic Variant (c.1198G>T)
por: Ryu, Sohee, et al.
Publicado: (2019)

Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC in Slovak HBOC families
por: Cierniková, S, et al.
Publicado: (2005)

A novel c.563 T>G, p.L189R lamin A/C mutation in identical twins with dilated cardiomyopathy
por: Lee, Euijae, et al.
Publicado: (2017)

First Pediatric Case of Autosomal Recessive Homozygotic Bestrophinopathy due to Homozygous Mutation c.187G>C p. in Two Brothers
por: Bittmann, Stefan, et al.
Publicado: (2022)

BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer
por: Kondo, Tomohiro, et al.
Publicado: (2020)

A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history
por: Gómez García, Encarna B, et al.
Publicado: (2009)

Novel Pathogenic Variant of SPAST (c.1413+4A>G) in a Patient with Hereditary Spastic Paraplegia
por: Yang, Jiwon, et al.
Publicado: (2019)

Screening of BRCA1 variants c.190T>C, 1307delT, g.5331G>A and c.2612C>T in breast cancer patients from North India
por: Kour, Akeen, et al.
Publicado: (2020)

The BRCA2 c.68‐7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity
por: Colombo, Mara, et al.
Publicado: (2018)

Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
por: Bjørnslett, Merete, et al.
Publicado: (2012)

Management of the asymptomatic BRCA mutation carrier
por: Teller, Paige, et al.
Publicado: (2010)

Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families
por: NOVAKOVIĆ, SRDJAN, et al.
Publicado: (2012)

DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3
por: Yang, Rachel L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bq77nv684b0clivp5rdit2r0bu